News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INSYS Therapeutics Announces Submission of NDA for Fentanyl SL Spray



3/7/2011 5:24:57 PM

PHOENIX--(BUSINESS WIRE)--Insys Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC: NEOL.PK) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for its cancer pain product candidate, Fentanyl SL Spray.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES